Jianshi Technology-B (09877) rose by more than 22%. As of press release, it was up 19.05% to HK$4, with a turnover of HK$25.9636 million.
The Zhitong Finance App learned that Jianshi Technology-B (09877) had the highest increase of 22%. As of press release, it had risen 19.05% to HK$4, with a turnover of HK$25.9636 million.
According to the news, Jianshi Technology's 2023 financial report shows that the company's net loss due to mother narrowed to 372 million yuan last year; as of December 31, 2023, the company's book monetary capital was 928 million yuan, an increase of 27.6% over the previous year, mainly due to strict control of costs and expenses and refunds from the sale of shares in the early financial investments. The company has sufficient monetary capital to ensure long-term sustainable operation and development.
In 2023, the company will continue to promote clinical and commercialization of the core product LUX-Valve series products on a global scale, as well as promote clinical research and development work in other product pipelines under development, enrich the variety of products, and plans to comprehensively promote commercialization after product approval in 2024. Furthermore, in February of this year, LUX-VALVE Plus completed the first clinical implantation procedure in Latin America in Brazil, further expanding the scope of product promotion.